Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study

The retrospective study analyzed 126 patients with alopecia areata who were treated with tofacitinib from February 2021 to December 2022. The median treatment duration was 23 weeks, and the median all-cause survival time was 44 weeks. The drug retention rates at 12, 24, and 48 weeks were 90.0%, 66.4%, and 42.3% respectively. The most common reason for discontinuation was complete remission or satisfaction. Among the 80 patients treated with tofacitinib for over 6 months, the overall complete response rate at 24 weeks was 33.8% (27/80). No life-threatening serious adverse events were reported. The study found that sex is an independent risk factor in predicting patient outcomes. The study concluded that tofacitinib is highly effective and safe in treating alopecia areata, with a satisfactory drug survival rate.